Literature DB >> 3356487

Survival patterns for malignant mesothelioma: the SEER experience.

R Spirtas1, R R Connelly, M A Tucker.   

Abstract

Statistical analyses of 1,475 histologically confirmed cases of malignant mesothelioma ascertained through the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute for the years 1973-1984 showed age at diagnosis, sex, stage of disease, type of treatment, and geographic area of residence to be important predictors of patient survival, although type of treatment may be confounded with prognostic factors (patients selected for surgical treatment tended to have better performance status than other patients). Women below the age of 50 had an unusually long survival, even after adjustment for the effects of other variables in the model. A relatively large proportion of female cases had site of disease designated as peritoneum, but site was not a significant prognostic factor. These results suggest that age, gender and stage of disease should be carefully considered in designing and analyzing clinical trials for persons with mesothelioma. Survival was shorter in the 4 SEER registries which had shipbuilding as a major industry than in the others with less potential asbestos exposure, offering weak support for the hypothesis that asbestos-exposed cases of mesothelioma have worse survival experience than other cases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356487     DOI: 10.1002/ijc.2910410409

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

2.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

3.  Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression.

Authors:  Hiroshi Hirano; Takashi Fujisawa; Koichi Maekawa; Eriko Ohkubo; Akira Okimura; Kozo Kuribayashi; Takashi Nakano; Keiji Nakasho; Takashi Nishigami
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

4.  A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.

Authors:  Shuai Wang; Ke Ma; Zongwei Chen; Xiaodong Yang; Fenghao Sun; Yulin Jin; Yu Shi; Wei Jiang; Qun Wang; Cheng Zhan
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

5.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Authors:  Robert Ryan Meyerhoff; Chi-Fu Jeffrey Yang; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

6.  Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.

Authors:  Ben Davidson; Lina Vintman; Eyal Zcharia; Carlos Bedrossian; Aasmund Berner; Søren Nielsen; Neta Ilan; Israel Vlodavsky; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

Review 8.  What is the survival after surgery for localized malignant pleural mesothelioma?

Authors:  Sandra M Gelvez-Zapata; Daniel Gaffney; Marco Scarci; Aman S Coonar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-17

9.  Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level.

Authors:  Alessandro Marinaccio; Alberto Scarselli; Alessandra Binazzi; Pierluigi Altavista; Stefano Belli; Marina Mastrantonio; Roberto Pasetto; Raffaella Uccelli; Pietro Comba
Journal:  Int Arch Occup Environ Health       Date:  2007-12-20       Impact factor: 3.015

10.  Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.

Authors:  Marina Vivero; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2017-09-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.